Beta Drugs
Ticker > Company >

Beta Drugs share price

Beta Drugs Ltd.

NSE: BETA SECTOR: Pharmaceuticals & Drugs  80k   184   10

2016.70
-43.35 (-2.10%)
NSE: 23 Dec 03:40 PM

Price Summary

Today's High

₹ 2079.95

Today's Low

₹ 2000

52 Week High

₹ 2326

52 Week Low

₹ 1060.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1938.81 Cr.

Enterprise Value

₹ 1917.29 Cr.

No. of Shares

0.96 Cr.

P/E

88.38

P/B

16.71

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  120.67

CASH

₹ 27.2 Cr.

DEBT

₹ 5.68 Cr.

Promoter Holding

66.73 %

EPS (TTM)

₹  22.82

Sales Growth

25.18%

ROE

20.67 %

ROCE

27.27%

Profit Growth

16.58 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.18%
3 Year35.49%
5 Year27.76%

Profit Growth

1 Year16.58%
3 Year46.49%
5 Year23.25%

ROE%

1 Year20.67%
3 Year20.85%
5 Year17.77%

ROCE %

1 Year27.27%
3 Year27.37%
5 Year22.97%

Debt/Equity

0.0489

Price to Cash Flow

91.51

Interest Cover Ratio

29.1514

CFO/PAT (5 Yr. Avg.)

0.982491141880378

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 66.73 0.00
Jun 2024 66.73 0.00
Mar 2024 66.73 0.00
Dec 2023 66.73 0.00
Sep 2023 66.73 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 35.4876411760403% for the Past 3 years.
  • Company has been maintaining healthy ROE of 20.8524098472561% over the past 3 years.
  • Company has been maintaining healthy ROCE of 27.3707300682481% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 29.1514.
  • The company has an efficient Cash Conversion Cycle of 23.8611 days.
  • Company has a healthy liquidity position with current ratio of 2.2393.
  • The company has a high promoter holding of 66.73%.

 Limitations

  • The company is trading at a high PE of 88.38.
  • The company is trading at a high EV/EBITDA of 55.5657.

Quarterly Result (All Figures in Cr.)
Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 65.32 79.46 124.85 157.87 197.62
Total Expenditure 53.57 64.15 99.66 126.68 164.1
Operating Profit 11.75 15.31 25.18 31.2 33.53
Other Income 0.42 0.61 0.86 1.04 1.73
Interest 0.64 0.77 0.41 0.84 1.05
Depreciation 2.58 5.27 5.47 6.19 4.72
Exceptional Items 0 0 0 0 0
Profit Before Tax 8.95 9.88 20.16 25.21 29.48
Tax 1.85 2.9 5.92 6.39 7.55
Net Profit 7.1 6.98 14.25 18.82 21.94
Adjusted EPS (Rs.) 7.39 7.26 14.82 19.57 22.82

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 9.61 9.61 9.61 9.61 9.61
Total Reserves 46.83 53.8 67.85 86.64 106.4
Borrowings 3.45 3.39 5.15 3.73 3.62
Other N/C liabilities 0.89 1.45 1.84 1.69 2.36
Current liabilities 22.59 20.34 30.06 35.22 53.26
Total Liabilities 83.37 88.59 114.51 136.89 175.26
Assets
Net Block 31.67 28.01 34.06 34.77 36.48
Capital WIP 0.08 1.9 0 0 0
Intangible WIP 0 0 0 0 0
Investments 6.12 6.54 6.54 6.55 5.77
Loans & Advances 7.18 5.81 6.89 6.78 13.68
Other N/C Assets 0 0.05 0.05 0.05 0.05
Current Assets 38.32 46.28 66.97 88.74 119.27
Total Assets 83.37 88.59 114.51 136.89 175.26
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 8.95 9.88 20.16 25.21 29.48
Adjustment 1.57 4 3.11 0.42 -6.29
Changes in Assets & Liabilities -4.43 -2.28 -4.51 -15.41 -2.01
Tax Paid 0 0 0 0 0
Operating Cash Flow 6.09 11.6 18.76 10.23 21.19
Investing Cash Flow -14.33 -3.15 -12.72 -5.82 -11.02
Financing Cash Flow 9.48 -4.34 1.27 -2.19 -0.76
Net Cash Flow 1.24 4.1 7.31 2.21 9.4

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 66.73 66.73 66.73 66.73 66.73
aditi batra 0.01 0.01 0.01 0.01 0.01
heena batra 0.01 0.01 0.01 0.01 0.01
neeraj batra 65.96 65.96 65.96 65.96 65.96
rahul batra 0.41 0.41 0.41 0.41 0.41
varun batra 0.35 0.35 0.35 0.35 0.35
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 33.27 33.27 33.27 33.27 33.27
ashish kacholia 5.78 5.78 5.78 5.78 5.78
bsas infotech limited 1.27 1.27 1.27 - 1.27
llp 0.02 - - 0.02 0.07
onkar singh 1.05 1.05 1.05 1.05 1.05
suryavanshi commotrade pr... 6.74 6.74 6.74 - 6.74

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

 No Latest News available for this company.
Report us

Beta Drugs Stock Price Analysis and Quick Research Report. Is Beta Drugs an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Beta Drugs and its performance over the period of time. Beta Drugs stock price today is Rs 2016.7.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Beta Drugs cash from the operating activity was Rs 21.1872 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Beta Drugs has a Debt to Equity ratio of 0.0489 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Beta Drugs , the EPS growth was 16.5839 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Beta Drugs has OPM of 16.9646195970362 % which is a good sign for profitability.
     
  • ROE: Beta Drugs have a healthy ROE of 20.669 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Beta Drugs is Rs 2016.7. One can use valuation calculators of ticker to know if Beta Drugs share price is undervalued or overvalued.
Last Updated on:
Brief about Beta Drugs

Beta Drugs Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Beta Drugs Limited is a leading pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of therapeutic products. With a strong presence in the market, Beta Drugs Limited is committed to providing high-quality pharmaceuticals that meet global standards.

Beta Drugs Limited: Share Price

Stay updated with the latest share price information of Beta Drugs Limited on our stock analysis page. Our comprehensive stock analysis tools provide real-time data, allowing investors to make informed decisions based on the latest market trends and developments.

Beta Drugs Limited: Balance Sheet

Access the balance sheet of Beta Drugs Limited and analyze the company's financial position. Our pre-built screening tools help long-term investors assess the company's stability and growth potential. Furthermore, our premium features, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, enable investors to calculate fair value and determine the overall financial health of the company.

Beta Drugs Limited: Annual Report

Obtain the annual report of Beta Drugs Limited from our website. The annual report offers a comprehensive overview of the company's performance, achievements, and future prospects. Long-term investors can gain valuable insights into the company's strategy, financial results, and market outlook through the annual report.

Beta Drugs Limited: Dividend

Explore the dividend history of Beta Drugs Limited and stay updated with the latest payouts. Dividends play a significant role in long-term investing, and our stock analysis page provides information on the company's dividend track record.

Beta Drugs Limited: Quarterly Result

Analyze the quarterly results of Beta Drugs Limited using our stock analysis tools. By studying the company's performance on a quarterly basis, investors can assess its financial trajectory and identify trends. Our premium features, including DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, offer a comprehensive view of the company's profitability and operational efficiency.

Beta Drugs Limited: Stock Price

Get real-time stock price updates for Beta Drugs Limited on our stock analysis page. Our easy-to-use platform enables investors to monitor price movements, track historical data, and analyze trends. Stay informed and make well-informed investment decisions.

Beta Drugs Limited: Price Chart

Visualize the price movements of Beta Drugs Limited through our interactive price charts. Our user-friendly charts provide a graphical representation of the company's stock performance, assisting long-term investors in identifying patterns and potential buying or selling opportunities.

Beta Drugs Limited: News

Stay up-to-date with the latest news and updates related to Beta Drugs Limited. Our stock analysis page curates news articles from reliable sources, ensuring that investors have access to the most relevant and timely information. Our news section helps investors stay informed about market developments, regulatory updates, and any significant events affecting the company.

Beta Drugs Limited: Concall Transcripts

Access the conference call transcripts of Beta Drugs Limited on our website. Transcripts provide insights into management discussions, strategies, and outlooks. By studying these transcripts, investors can gain a deeper understanding of the company's operations and future plans.

Beta Drugs Limited: Investor Presentations

Download investor presentations from Beta Drugs Limited to gain a comprehensive view of the company's growth plans, strategy, and market opportunities. These presentations offer valuable information to long-term investors looking to understand the company's vision and potential.

Beta Drugs Limited: Promoters

Learn about the promoters of Beta Drugs Limited, the key individuals behind the company's success. The promoters play a crucial role in shaping the company's strategy and overall direction. Understanding the background and experience of the promoters helps investors assess the company's leadership.

Beta Drugs Limited: Shareholders

Discover the major shareholders of Beta Drugs Limited. Knowing the key investors and their stake in the company provides insights into the market sentiment and confidence in the company's future prospects.

At Beta Drugs Limited, we understand the importance of providing investors with comprehensive stock analysis tools and resources. Our stock analysis page offers a wide range of information, including company profile, share price, balance sheet, annual reports, dividend history, quarterly results, stock price charts, news updates, concall transcripts, investor presentations, details about promoters, and major shareholders. With our premium features, investors can calculate fair value using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Access all these resources on our website and make informed decisions for long-term investing.

Read More
X